Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Erika Vacchelli, Norma Bloy, Fernando Aranda, Aitziber Buqué, Isabelle Cremer, Sandra Demaria, Alexander Eggermont, Silvia Chiara Formenti, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology 5:9.
Read now
Read now
A Covre, S Coral, H Nicolay, G Parisi, C Fazio, F Colizzi, E Fratta, A M Di Giacomo, L Sigalotti, P G Natali & M Maio. (2015) Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology 4:8.
Read now
Read now
Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology 4:1.
Read now
Read now
Articles from other publishers (13)
Simona Bořilová, Peter Grell, Ondřej Bílek & Igor Kiss. (2020) Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. Onkologie 14:5, pages 205-212.
Crossref
Crossref
Paolo D’Arrigo, Martina Tufano, Anna Rea, Vincenza Vigorito, Nunzia Novizio, Salvatore Russo, Maria Fiammetta Romano & Simona Romano. (2020) Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry 27:15, pages 2402-2448.
Crossref
Crossref
William R. Gwin & Mary L. Disis. 2018. Immunotherapy in Translational Cancer Research. Immunotherapy in Translational Cancer Research
228
251
.
Saranya Chumsri & Keith L. Knutson. 2018. Immunotherapy in Translational Cancer Research. Immunotherapy in Translational Cancer Research
1
11
.
Victoria A Brentville, Suha Atabani, Katherine Cook & Lindy G Durrant. (2018) Novel tumour antigens and the development of optimal vaccine design. Therapeutic Advances in Vaccines and Immunotherapy 6:2, pages 31-47.
Crossref
Crossref
A. Scherpereel, M.-C. Willemin, E. Wasielewski & X. Dhalluin. (2018) Immunothérapie anti-tumorale dans le mésothéliome pleural malin. Revue des Maladies Respiratoires 35:4, pages 465-476.
Crossref
Crossref
Lysanne A. Lievense, Daniel H. Sterman, Robin Cornelissen & Joachim G. Aerts. (2017) Checkpoint Blockade in Lung Cancer and Mesothelioma. American Journal of Respiratory and Critical Care Medicine 196:3, pages 274-282.
Crossref
Crossref
Arnaud Scherpereel. (2017) Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future. Current Pulmonology Reports 6:2, pages 155-159.
Crossref
Crossref
Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao, Heinz Zwierzina, Lisa H. Butterfield & Bernard A. Fox. (2016) Novel technologies and emerging biomarkers for personalized cancer immunotherapy. Journal for ImmunoTherapy of Cancer 4:1.
Crossref
Crossref
A. Scherpereel. (2016) Traitement du mésothéliome pleural malin en 2016. Revue des Maladies Respiratoires Actualités 8:5, pages 445-456.
Crossref
Crossref
A. Scherpereel. (2015) Mésothéliomes pleuraux malins. Revue des Maladies Respiratoires Actualités 7:4, pages 511-518.
Crossref
Crossref
Mayura Meerang, Andreas Boss, David Kenkel, Angela Broggini-Tenzer, Karima Bérard, Olivia Lauk, Stephan Arni, Walter Weder & Isabelle Opitz. (2015) Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†. European Journal of Cardio-Thoracic Surgery 47:1, pages e34-e41.
Crossref
Crossref
Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, Ornella Cutaia, Aldo Morra, Ramy Ibrahim & Michele Maio. (2014) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunology, Immunotherapy 64:1, pages 105-112.
Crossref
Crossref